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Table 1. Comparison between non-treated uremic rats (Control)Mechanism of oral absorbent AST-120 in lipid abnormalities
and AST-treated uremic rats (AST)in experimental uremic rats.
Background. We have reported that oral sorbent AST-120 Control AST
(AST) is effective in delaying the induction of dialysis in pa-
Body weight g 430639 423 629tients with chronic renal failure (CRF) because of its effect on
BUN mg/dl 72615 53 613alipid metabolism. To clarify the precise mechanism of AST in
Creatinine mg/dl 1.660.3 1.2 60.2blipid abnormalities in CRF, we examined the effect of AST CCr ml/min 0.6560.12 0.82 60.16on plasma lipid profile, total bile acids (TBA), and lipoprotein UAlb mg/day 82.2620.9 28.4 626.4a
lipase (LPL) activity in experimental uremic rats. T cholesterol mg/day 195653 127 630a
Methods. Uremic rats were prepared using male Wistar rats Triglycerides mg/dl 209655 121 640a
TBA lmol/liter 19.662.6 8.8 63.5bby ligating 5/6 of the renal artery. Uremic rats were randomly
LPL lmol FFA/min/hr 0.1560.03 0.22 60.06adivided into two groups as follows: a control group in which
rats were maintained on the standard diet and an AST group Abbreviations are: BUN, blood urea nitrogen; CCr, creatinine clearance; UAlb,
urinary albumin excretion; TBA, total bile acids; LPL, lipoprotein lipase activity.in which rats were maintained on a diet containing 5 g of AST
Data are mean 6 sd.per 100 g of standard diet for 10 weeks. Plasma LPL activity was
a P , 0.05, b P , 0.01measured as free fatty acid (FFA) generation after intravenous
administration of heparin.
Results. Plasma creatinine at 1.5 6 0.1 mg/dl was lower in
the AST group than the 1.9 6 0.5 mg/ml level in the control
of CRF [5, 6], and lipid-lowering agents have been showngroup. AST significantly decreased plasma total cholesterol
from 192 6 29 to 142 6 25 mg/dl, triglycerides from 198 6 71 to prevent the progression of CRF [7, 8]. We have re-
to 99 6 38 mg/dl, and TBA from 19.6 6 2.6 mmol/liter to ported that AST-120 improved lipid abnormalities in
8.8 6 3.5 mmol/ml. Plasma LPL activity at 0.22 6 0.01 mmol experimental uremic rats [9]. In this study, to clarify one
FFA/min/hr was significantly higher in the AST group than
of the mechanisms of AST-120 on delaying the progres-0.15 6 0.03 mmol FFA/min/hr in the control group.
sion of CRF, we examined the effect of AST-120 on theConclusions. These results suggest that AST may improve
plasma lipid abnormalities by binding to bile acids in the intesti- plasma lipid profile in experimental uremic rats.
nal lumen and preventing their reabsorption and inhibiting the
reduction of LPL activity in experimental uremic rats.
METHODS
Experimental design
It has been found that oral sorbent AST-120 (Kureha Uremic rats were prepared using Jc1-Wiater male rats
Chemical Industry, Tokyo, Japan) is effective in delaying (CLEA Japan, Tokyo, Japan) weighing 220 to 260 g by
the induction of dialysis therapy in patients with chronic ligating five sixths of the renal artery according to the
renal failure (CRF) [1]. One of the mechanism by which previously reported methods [2]. In brief, under intra-
AST-120 postpones the initiation of dialysis therapy may peritoneal anesthesia with sodium pentobarbital, two of
be the reduction of indoxyl sulfate, which is a stimulating the three branches of the left renal artery were ligated
factor for the progression of CRF [2–4]. However, the through a lateral incision. One week after the first opera-
precise mechanism of AST-120 is still not clear. Recently, tion, the hilum of the right kidney was totally ligated
it has been proposed that plasma lipid abnormalities may via a lateral incision performed under ether anesthesia.
play an important role in the pathogenesis of progression Thus, five sixths of the normal kidney mass became ne-
phrectomized. Uremic rats were randomly divided into
two experimental groups as follows: a control groupKey words: chronic renal failure, lipoprotein lipase activity, total bile
acids. (N 5 6), in which the rats were maintained on the stan-
dard diet, and an AST group (N 5 7), in which rats were 1999 by the International Society of Nephrology
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Fig. 1. Time course changes of plasma tri-
glycerides (TG) and lipoprotein lipase activity
(LPL) in AST-nontreated uremic rats (con-
trol) and AST-treated rats (AST).
maintained on a diet containing 5 g of AST per 100 g (CCr), urinary albumin excretion (UAlb), TC, TG, TBA,
and LPL activity between the control group and the ASTof standard diet for 10 weeks.
group. Body weight was the same in both groups. BUN,
Biochemical studies creatinine, and UAlb were significantly lower in the AST
Plasma total cholesterol (TC), triglycerides (TG), and group than in the control group. CCr was higher in the
total bile acids (TBA) were measured by an autoana- AST group than in the control group, but the difference
lyzer. Plasma lipoprotein lipase (LPL) activity was deter- was not significant. TC and TG were significantly lower
mined as free fatty acid (FFA) generation at 10 minutes in the AST group than in the control group. TBA was
after intravenous administration of 10 U/kg body wt of significantly lower and LPL activity was significantly
heparin. higher in the AST group than in the control group. Time
course changes of TG and LPL activities in both groups
RESULTS are shown in Figure 1. LPL activity was decreased ac-
Table 1 shows a comparison of body weight, blood cording to the progression of uremia in the control group.
However, the reduction of LPL activity was significantlyurea nitrogen (BUN), creatinine, creatinine clearance
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inhibited by AST treatment. The difference was signifi- to bile acid-binding resins and by inhibiting the reduction
of LPL activity in experimental uremic rats, which con-cant at 10 weeks after administration of AST-120. TG
was increased according to the progression of uremia tributed to the prevention of progressive renal disease.
in the control group. On the other hand, TG was not
Reprint requests to Minoru Yamakado, M.D., Department of Health
increased significantly in the AST group. The difference Care, Mitsui Memorial Hospital, 1 Kanda Izumicho, Chiyoda-ku,
Tokyo 101-0024, Japan.in TG was significant between the groups at 8 and 10
weeks after treatment with AST-120.
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